Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook
Alnylam Pharmaceuticals Analyst Ratings
JPMorgan Chase Raises Price Target on Alnylam Pharmaceuticals to $248 From $160
Mettler-Toledo Intl Analyst Ratings
Evercore ISI Adjusts Price Target on Mettler-Toledo International to $1,390 From $1,375, Maintains In-line Rating
Gilead Sciences Analyst Ratings
RBC Capital Reiterates Sector Perform on Gilead Sciences, Maintains $74 Price Target
Alnylam Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $150 Price Target
Morgan Stanley Sticks to Its Hold Rating for BioNTech SE (BNTX)
Gilead Sciences (GILD) Receives a Hold From RBC Capital
IQVIA Hldgs Analyst Ratings
Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Amgen Analyst Ratings
Argus Research Maintains Buy on Amgen, Raises Price Target to $340
Alnylam Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Outperform on Biogen, Maintains $317 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Maintains $1152 Price Target
Stifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $295